Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) sounds like it was designed by someone who really wanted to make neurologists' lives difficult. It's a genetic condition where a mutant protein clumps up and deposits in nerve tissue, progressively destroying the peripheral nervous system. Treatments exist, but they're not great. The disease keeps marching forward, and patients keep losing sensation and motor function.
But a study in Cell Reports just found something that might change the equation: a molecule called Rac1 that goes into overdrive before nerves actually start dying. Block Rac1, and the nerve damage doesn't happen. Even if the misfolded protein is still accumulating. That's a pretty big deal.
The Early Warning Nobody Was Looking For
Here's what usually happens in this disease. Mutant transthyretin protein misfolds and aggregates, forming deposits called amyloid. These deposits accumulate in and around peripheral nerves. Eventually, the nerves die. Patients lose feeling in their feet, then their hands, then things get progressively worse from there.
Most research has focused on stopping the protein aggregation itself. That makes sense. If you can prevent the clumps from forming, you should prevent the disease. But what if there's another way?
The researchers studying a mouse model of the disease noticed something interesting: before the nerves actually showed visible degeneration, their internal structure was already falling apart. Specifically, the cytoskeleton was in trouble.
The cytoskeleton is the cell's internal scaffolding. In neurons, it's especially important because nerve cells are incredibly long and thin. They need robust structural support and efficient transport systems to move cargo from the cell body all the way down axons that can stretch over a meter in humans. When the cytoskeleton breaks down, it's like the supporting beams of a building starting to buckle. The structure is doomed before anyone notices from the outside.
Meet Rac1, the Hyperactive Troublemaker
So what was causing the cytoskeletal collapse? The finger pointed at Rac1, a small molecule that acts as a molecular switch controlling how the actin cytoskeleton reorganizes. Actin is one of the main structural proteins in cells, forming the leading edges that allow cells to move and the internal networks that maintain cell shape.
In healthy neurons, Rac1 activity is carefully regulated. Turn it on when you need to reorganize actin. Turn it off when you're done. Simple enough.
In the disease model, Rac1 was stuck in the "on" position. Way too active, way too often. It's like having a construction worker who refuses to stop hammering even after the building is finished. All that unnecessary activity was disrupting the normal cytoskeletal organization, causing the scaffolding to become disorganized and dysfunctional.
Here's the exciting part: when the researchers inhibited Rac1, the cytoskeletal defects were rescued. The nerves didn't degenerate. And this worked even though the protein aggregation, the supposed root cause of the disease, was still happening.
Think about that for a second. You don't have to fix the underlying problem if you can prevent the downstream damage. It's like fireproofing a building. You haven't prevented the fire from starting, but you've made sure it can't burn the place down.
When Mice and Humans Tell the Same Story
Mouse models are great, but they don't always translate to humans. So the researchers dug into human genetics looking for supporting evidence.
They found it. In patients with late-onset forms of the disease (meaning their symptoms started later in life, which generally indicates a less severe course), there was a variant in a gene called RACGAP1. What does RACGAP1 do? It encodes a protein that inactivates Rac1.
So in humans with natural genetic variation that reduces Rac1 activity, the disease progresses more slowly. That's independent confirmation that dialing down Rac1 is neuroprotective. When your mouse experiments and your human genetics studies point in the same direction, you're probably onto something real.
What This Means for Patients
ATTRv-PN already has some treatments. There are drugs that stabilize transthyretin so it doesn't misfold, and newer gene silencing therapies that reduce how much transthyretin the body makes. These help, but the disease often continues to progress.
Adding a Rac1 inhibitor to the mix could be a new angle of attack. You'd be hitting the disease from a different direction, targeting the damage mechanism rather than the protein aggregation. Combined therapies might work better than single approaches.
And unlike targeting the protein itself, which has to happen before aggregation occurs, the Rac1 approach seems to work even when protein clumps are already present. That could matter for patients who are diagnosed after significant aggregation has already happened.
The path from discovery to therapy is long, and Rac1 inhibitors would need to be carefully designed to avoid side effects (since Rac1 does useful things in other contexts). But having a validated target is the first step, and this study makes a strong case that Rac1 deserves attention.
Reference: Magalhães J, et al. (2025). Rac1 inhibition prevents axonal cytoskeleton dysfunction in transthyretin amyloid polyneuropathy. Cell Reports. doi: 10.1016/j.celrep.2025.116411 | PMID: 41066240
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.